C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2026)

C4 Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $83.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 4.02% year-over-year to $83.5 million; the trailing twelve-month figure through Mar 2026 stood at $314.9 million (down 18.57% YoY), and the FY2025 full-year result was $101.0 million, up 9.94% from the prior year.
• Non-Current Assets for Q1 2026 stood at $83.5 million, down from $101.0 million in the prior quarter.
• The five-year high for Non-Current Assets was $212.5 million in Q1 2022, with the low at $58.6 million in Q3 2025.
• Average Non-Current Assets over 5 years is $112.9 million, with a median of $105.0 million recorded in 2024.
• Year-over-year, Non-Current Assets surged 308.76% in 2022 and tumbled 44.68% in 2023.
• Tracing CCCC's Non-Current Assets over 5 years: stood at $143.3 million in 2022, then retreated by 26.54% to $105.3 million in 2023, then retreated by 12.76% to $91.8 million in 2024, then increased by 9.94% to $101.0 million in 2025, then slipped by 17.31% to $83.5 million in 2026.
• The last three Non-Current Assets figures came in at $83.5 million (Q1 2026), $101.0 million (Q4 2025), and $58.6 million (Q3 2025), per Business Quant data.

Peer Comparison